"Laboratory tests of the HIV vaccine models on samples of HIV-infected cells began in February 2005. Initial results should be available later in 2005. If the models succeed, Microsoft Corp. will do algorithmic analysis to determine if the multiple epitopes reduce the effectiveness of the vaccines, a phenomenon called immunodominance."